Science and Technology Daily, Beijing, March 25 (Reporter Qu Jian) China National Pharmaceutical Group Co., Ltd. announced in Beijing on the 25th that another effective drug for new coronary pneumonia, Huashibaidu Granules, was officially launched.
This is one of the first batch of Chinese traditional Chinese medicine compound preparations with completely independent intellectual property rights that are tailored to the ancient classics of the epidemic. It is also one of the "three medicines and three prescriptions" for the effective treatment of new coronary pneumonia.
Prior to March 2, the "three parties" including Huashibaidu Granules were approved by the State Food and Drug Administration for listing.
Sun Da, deputy director of the State Administration of Traditional Chinese Medicine, said that this is a full recognition of the clinical efficacy of traditional Chinese medicine in the epidemic and the accumulation of scientific data. It is a major and happy event in the development of traditional Chinese medicine.
Huang Luqi, academician of the Chinese Academy of Engineering and dean of the Chinese Academy of Chinese Medical Sciences, emphasized: "Today's meeting is not only the launch of a medicine, but also a way of reforming the review and approval system of Chinese medicine in accordance with the laws of Chinese medicine. It is a milestone." He introduced, Since the outbreak of the new crown pneumonia, the first batch of national TCM medical teams (the medical team of the Chinese Academy of Chinese Medical Sciences) in Wuhan’s first-line anti-epidemic clinics screened out effective prescriptions. The transformation of the results of the Huashibaidu formula is effective for the treatment of new crown pneumonia. One of the "three medicines and three prescriptions" of prescriptions is included in the sixth, seventh and eighth editions of the National Guidelines for the Diagnosis and Treatment of Novel Coronavirus Pneumonia.
Liu Jingzhen, Chairman of Sinopharm Group, said that he will fully support the realization of large-scale mass production of Huashibaidu granules, and provide strong support for traditional Chinese medicine to play its unique advantages and role in responding to new and major public health events.
Cheng Xueren, general manager of Yifang Pharmaceutical, a subsidiary of Sinopharm Group, disclosed that Yifang Pharmaceutical, as the undertaking unit of the industrialization project of Huashibaidu granules, has made relevant preparations for its industrialization to fully guarantee the supply demand in the market.
The next step will also promote the overseas registration of Huashibaidu granules.